NEWS RELEASES

2022

- Salix Will Present Rifaximin Data at AASLD's The Liver Meeting® 2022

- Salix Will Present XIFAXAN® (Rifaximin), TRULANCE® (Plecanatide) and RELISTOR® (Methylnaltrexone Bromide) Data at The American College of Gastroenterology® 2022 Annual Scientific Meeting

- Salix Pharmaceuticals Releases Liver Health Annual Trends Report Underscoring Challenges in Caring for Growing Chronic Liver Disease and Cirrhotic Patient Population

- Salix Pharmaceuticals Applauds Implementation of K76.82 – a New ICD-10 Code for Hepatic Encephalopathy

- Salix Supports CMS Announcement of First ICD-10 Code for Hepatic Encephalopathy (HE)

- Salix Announces 2022 Gastrointestinal Health Scholars Program Winners

- Salix to Share New Data from XIFAXAN® (Rifaximin) Clinical Research at EASL's International Liver Congress™ 2022

- Salix Pharmaceuticals To Share New Data At Digestive Disease Week® 2022

- Salix Pharmaceuticals Will Present Scientific Data At The Society Of Hospital Medicine Converge 2022

- Half Of IBS Patients Surveyed Report IBS Symptoms More Challenging To Manage In The Past Year

- New Data on Cost Impact of Treating Opioid-Induced Constipation (OIC) with FDA-Approved Medications, Including Salix's RELISTOR® Subcutaneous Injection (Methylnaltrexone Bromide), in The Emergency Department Is Published in Advances In Therapy

- Salix and Colon Cancer Coalition Join Forces for 'Faces of Blue' Story Series to Raise Awareness of Colorectal Cancer Screenings

- Salix Announces 2022 Gastrointestinal Health Scholars Program

2021

- Relistor® (Methylnaltrexone Bromide) Data is Published in the Journal of Emergency Medicine

- Salix Brings Educational Resources on Constipation Into the Homes of Patients and Caregivers for Constipation Awareness Month

- Salix Will Share New Rifaximin Data At AASLD's The Liver Meeting™ 2021

- New Report Reveals Barriers To Quality Care For Chronic Liver Disease Patients, A Cause Of Morbidity And Mortality Projected To Grow In The United States

- Salix Will Feature New Data At The American College Of Gastroenterology® 2021 Annual Scientific Meeting

- Salix Will Share RELISTOR® (Methylnaltrexone Bromide) Data At The American Society For Pain Management Nursing (ASPMN) 31st National Conference

- Salix Will Share RELISTOR® (Methylnaltrexone Bromide) Data At PAINWeek 2021

- Salix Announces 2021 Gastrointestinal Health Scholars Program Winners

- Salix Will Share TRULANCE® (Plecanatide) Data At The 2021 AANP National Conference

- Salix Will Share RELISTOR® (Methylnaltrexone Bromide) Data Analysis at the 2021 American Society of Clinical Oncology Annual Meeting and 2021 Annual Meeting of the Multinational Association of Supportive Care in Cancer

- Salix Will Feature New Data At Digestive Disease Week® 2021

- Salix Pharmacetuicals Will Present Scientific Data Featuring Post Hoc Analyses For RELISTOR® (Methylnaltrexone Bromide) At ASRA's 46th Annual Spring Meeting

- New Report Reveals That More Than One-Third of IBS Patients Surveyed State It Has Been More Challenging To Manage Their Symptoms During The COVID-19 Pandemic

- Salix Launches GastroHub for Advanced Practice Providers, an Educational Website Designed To Provide Nurse Practitioners and Physician Assistants With Relevant Information for Treating IBS-D and HE

- Colon Cancer Coalition and Salix to Launch Year-Long Campaign to Raise Awareness

- Salix Announces 2021 Gastrointestinal Health Scholars Program

2018

- Salix And Alfasigma Will Initiate Late-Stage Program To Study Rifaximin In Patients With Postoperative Crohn's Disease

- Salix to Present Clinical Data for XIFAXAN® (RIFAXIMIN) and PLENVU® at the American College of Gastroenterology Annual Meeting

- Salix Resolves Legacy SEC Investigation With No Penalty

- Dova Pharmaceuticals and Salix Enter Into Exclusive Co-Promotion Agreement For DOPTELET® (Avatrombopag)

- Bausch Health Announces Resolution Of XIFAXAN® Intellectual Property Litigation

- Salix Announces U.S. Launch of PLENVU®, the First and Only 1-Liter PEG Bowel Cleansing Preparation for Colonoscopies

- US WorldMeds And Salix Pharmaceuticals To Highlight Clinical Data For Opioid Withdrawal Treatment LUCEMYRA (lofexidine) At 2018 PAINWeek Conference

- US WorldMeds and Salix Announce U.S. Launch of LUCEMYRA (lofexidine) 0.18 Mg Tablets

- Salix Expands Microbiome Research And Discovery Through Strategic Collaboration With Cedars-Sinai Medical Center

- Salix And US WorldMeds Enter Into Exclusive Co-Promotion Agreement For Opioid Withdrawal Treatment LUCEMYRA (lofexidine)

- Salix To Highlight New Clinical Data During Digestive Disease Week

- Salix Receives FDA Approval For PLENVU®, Next Generation 1-Liter Bowel Cleansing Preparation For Colonoscopies

- Summary Judgment Granted Upholding The Validity Of Formulation Patent Protecting RELISTOR® Injection

- Arbitral Tribunal Decides In Favor Of Valeant In UCERIS Arbitration

- Salix Launches ‘Let’s Talk 2’ IBS Awareness Campaign

- Salix provides update on FDA submission for PLENVU®*